Proteine kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life

Publication date: Available online 15 June 2017
Source:Best Practice & Research Clinical Endocrinology & Metabolism
Author(s): Antonio Matrone, Laura Valerio, Letizia Pieruzzi, Carlotta Giani, Virginia Cappagli, Loredana Lorusso, Laura Agate, Luciana Puleo, David Viola, Valeria Bottici, Marzia Del Re, Eleonora Molinaro, Romano Danesi, Rossella Elisei
The last ten years have been characterized by the introduction in the clinical practice of new drugs named tyrosine kinase inhibitors for the treatment of several human tumors. After the positive conclusion of two international multicentric, randomized phase III clinical trials, two of these drugs, sorafenib and lenvatinib, have been recently approved and they are now available for the treatment of advanced and progressive radioiodine refractory thyroid tumors. We have been involved in most clinical trials performed with different tyrosine kinase inhibitors in different hystotypes of thyroid cancer thus acquiring a lot of experience in the management of both drugs and their adverse events. Aim of this review is to give an overview of both the rationale for the use of these inhibitors in thyroid cancer and the major results of the clinical trials. Some suggestions for the management of treated patients in the real life are also provided.



from # All Medicine by Alexandros G. Sfakianakis via ola Kala on Inoreader http://ift.tt/2sAHwNb
via IFTTT